AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 41 min read$NTRA

Moshkevich Solomon sold $655K of NTRA

Moshkevich Solomon (PRESIDENT, CLINICALDIAGNOSTICS) sold 3,000 shares of Natera, Inc. (NTRA) at an average of $218.43 ($217.52–$220.67, $0.66M total) across 4 trades on 2026-06-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Moshkevich Solomon
Published Jun 4, 2026, 1:05 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 4:03 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$NTRA
Neutral
medium confidence
Mentioned
$NTRA
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRANeutralLow
01

Why it matters

The disclosed sale provides fresh data on insider holdings and may influence short‑term trading sentiment.

02

Market read

A modest insider sell with limited market impact; traders may note the transaction but unlikely to drive price action.

03

What to watch

Potential upcoming clinical data releases or financing needs that prompted the insider to liquidate shares.

Relevance 4/10Novelty 4/10Timing: post‑market June 1, filed June 4

Background

SEC Form 4 filing discloses insider transactions; such filings are primary sources for corporate insider activity.

Company-level read

Ticker impact

$NTRANeutralMedium confidence
Context

President of Clinical Diagnostics sold 3,000 shares for $655K via a 10b5‑1 plan.

Expected impact

likely slight downward pressure as the market absorbs the insider sell.

Evidence & confidence

The transaction size is modest for a mid‑cap biotech, but the use of a pre‑arranged plan reduces surprise, limiting impact.

Market effects

Sector

Minimal; biotech sector unlikely to move on a single insider sell of this size.

Regional

None; the filing is U.S. specific and does not affect broader markets.

Global

Low; no global macro implications.

Counterpoint

What could challenge this read

The sale could be purely mechanical under a 10b5‑1 plan, not reflecting negative sentiment.

Key entities

  • person
    Moshkevich Solomon

    President, Clinical Diagnostics at Natera, reporting the sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

NTRA insider trading history →

Related articles

OCT 9
$NTRAHigh

Why Natera (NTRA) Stock Is Up Today

Natera (NTRA) stock rose 2.2% after the FDA granted Breakthrough Device designation to its multi-cancer early detection assay. The assay showed promising performance data across 12 cancer types. The company's shares are up 74.9% year-to-date, trading near a 52-week high of $425.64. Natera plans a commercial launch in Japan in 2027 for its Signatera test, approved as a companion diagnostic for bladder cancer.

financialcontent.com1 min
OCT 9
$NTRAHigh

Natera Receives FDA Breakthrough Device Designation for Multi-Cancer Early Detection Blood Test

Natera (NTRA) received FDA Breakthrough Device Designation for its multi-cancer early detection blood test, based on clinical data covering 12 cancer types. The designation accelerates regulatory review but does not guarantee approval. The test analyzes cell-free DNA to detect cancer signals and their likely origin. Natera aims to expand early cancer detection options, though clinical performance and benefits require further evaluation.

finance.yahoo.com2 min